Literature DB >> 20589870

Differential pattern of brain-specific CSF proteins tau and amyloid-β in Parkinsonian syndromes.

Sigurd D Süssmuth1, Ingo Uttner, Bernhard Landwehrmeyer, Elmar H Pinkhardt, Johannes Brettschneider, Axel Petzold, Bernd Kramer, Jörg B Schulz, Christian Palm, Markus Otto, Albert C Ludolph, Jan Kassubek, Hayrettin Tumani.   

Abstract

To evaluate cerebrospinal fluid (CSF) proteins reflecting processes of neurodegeneration and glial activation in progressive supranuclear palsy (PSP; Richardson's syndrome, n = 20; PSP-Parkinsonism, n = 7) and multiple system atrophy (MSA, n = 25), we analyzed tau, phosphorylated tau, amyloid-beta(1-42) (Abeta1-42), Abeta1-40, glial fibrillary acidic protein (GFAP), and CSF routine variables. Individuals with PSP-Parkinsonism and MSA had elevated tau levels when compared with Richardson's syndrome, Parkinson's disease (PD), and age-matched controls (P <or= 0.001). Ratios of P-tau/T-tau were significantly different in Parkinsonian syndromes. CSF Abeta1-42 was decreased only in patients with Richardson's syndrome. In a subset of Parkinsonian syndromes, we found elevated GFAP concentrations and increased CSF/serum albumin ratios. There were no correlations between biomarker concentrations and clinical scores in any of the diseases. In conclusion, this preliminary data show that changes in CSF tau and Abeta1-42 may indicate different protein processing in PSP patients and might, therefore, be relevant in the differentiation of PSP subtypes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20589870     DOI: 10.1002/mds.22895

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  8 in total

1.  Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy.

Authors:  Tommaso Schirinzi; Giulia Maria Sancesario; Giulia Di Lazzaro; Simona Scalise; Vito Luigi Colona; Paola Imbriani; Nicola Biagio Mercuri; Sergio Bernardini; Anthony E Lang; Antonio Pisani
Journal:  J Neural Transm (Vienna)       Date:  2018-06-14       Impact factor: 3.575

Review 2.  Diagnostic utility of fluid biomarkers in multiple system atrophy: a systematic review and meta-analysis.

Authors:  Shengri Cong; Chunchen Xiang; Hailong Wang; Shuyan Cong
Journal:  J Neurol       Date:  2020-03-11       Impact factor: 4.849

3.  Aβ1-15/16 as a potential diagnostic marker in neurodegenerative diseases.

Authors:  Magdalena Nutu; Philippe Bourgeois; Henrik Zetterberg; Erik Portelius; Ulf Andreasson; Stéphane Parent; Francesco Lipari; Sara Hall; Radu Constantinescu; Oskar Hansson; Kaj Blennow
Journal:  Neuromolecular Med       Date:  2012-12-07       Impact factor: 3.843

4.  A Panel of Plasma Biomarkers for Differential Diagnosis of Parkinsonian Syndromes.

Authors:  Qi Li; Zhen Li; Xiaoxuan Han; Xiao Shen; Fei Wang; Lipeng Bai; Zhuo Li; Rui Zhang; Yanlin Wang; Xiaodong Zhu
Journal:  Front Neurosci       Date:  2022-02-17       Impact factor: 4.677

Review 5.  The Role of Tau beyond Alzheimer's Disease: A Narrative Review.

Authors:  Eleonora Virgilio; Fabiola De Marchi; Elena Contaldi; Umberto Dianzani; Roberto Cantello; Letizia Mazzini; Cristoforo Comi
Journal:  Biomedicines       Date:  2022-03-24

Review 6.  Cerebrospinal Fluid Biomarkers in Multiple System Atrophy Relative to Parkinson's Disease: A Meta-Analysis.

Authors:  Dan Xie; Ling Feng; Hongyan Huang; Quanzhen Zhao; Pingping Ning; Qiuyan Shen; Haitao Lu; Fang Xu; Yanming Xu
Journal:  Behav Neurol       Date:  2021-05-31       Impact factor: 3.342

Review 7.  Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions.

Authors:  Nadia Magdalinou; Andrew J Lees; Henrik Zetterberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-04-01       Impact factor: 10.154

8.  Plasma Biomarkers Differentiate Parkinson's Disease From Atypical Parkinsonism Syndromes.

Authors:  Chin-Hsien Lin; Shieh-Yueh Yang; Herng-Er Horng; Che-Chuan Yang; Jen-Jie Chieh; Hsin-Hsien Chen; Bing-Hsien Liu; Ming-Jang Chiu
Journal:  Front Aging Neurosci       Date:  2018-04-27       Impact factor: 5.750

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.